Sobi completes acquisition of CTI BioPharma

Swedish Orphan Biovitrum AB, or Sobi, and CTI BioPharma announced the completion of the acquisition of CTI by Sobi through its indirect wholly owned subsidiary Cleopatra Acquisition Corp. As a result of the transaction, CTI has become an indirect wholly owned subsidiary of Sobi, and the common stock of CTI will cease to be traded on the Nasdaq Stock Market.